

William C Huang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/125000/publications.pdf>

Version: 2024-02-01

69
papers

2,974
citations

257450

24
h-index

168389

53
g-index

70
all docs

70
docs citations

70
times ranked

3508
citing authors

#	ARTICLE	IF	CITATIONS
1	Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial. <i>Journal of Urology</i> , 2022, 207, 61-69.	0.4	9
2	Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1312-1322.	1.6	42
3	Impact of type of minimally invasive approach on open conversions across ten common procedures in different specialties. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2022, 36, 6067-6075.	2.4	11
4	Does histologic subtype impact overall survival in observed T1a kidney cancers compared with competing risks? Implications for biopsy as a risk stratification tool. <i>International Journal of Urology</i> , 2022, , .	1.0	1
5	Machine learning decision support model for radical cystectomy discharge planning. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 453.e9-453.e18.	1.6	2
6	Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 382.e1-382.e6.	1.6	3
7	Application of the PRECISION Trial Biopsy Strategy to a Contemporary Magnetic Resonance Imaging-Targeted Biopsy Cohort—How Many Clinically Significant Prostate Cancers are Missed?. <i>Journal of Urology</i> , 2021, 205, 740-747.	0.4	13
8	Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): A multicenter phase 2 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4504-4504.	1.6	26
9	Neoadjuvant atezolizumab (A) with gemcitabine and cisplatin (GC) in patients (pts) with muscle-invasive bladder cancer (MIBC): A multicenter, single-arm, phase 2 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4517-4517.	1.6	9
10	Overall Survival of Biopsy-confirmed T1B and T2A Kidney Cancers Managed With Observation: Prognostic Value of Tumor Histology. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 280-287.	1.9	0
11	A workflow to generate patient-specific three-dimensional augmented reality models from medical imaging data and example applications in urologic oncology. <i>3D Printing in Medicine</i> , 2021, 7, 34.	3.1	16
12	Diagnostic role of urine cytology and ureteroscopic biopsies in detection of high grade upper tract urothelial carcinoma. <i>American Journal of Clinical and Experimental Urology</i> , 2021, 9, 221-228.	0.4	0
13	Current Landscape of Advanced and Metastatic Renal Cell Carcinoma Management. <i>Urologic Clinics of North America</i> , 2020, 47, xiii-xiv.	1.8	2
14	Prognostic Value of Histologic Subtype and Treatment Modality for T1a Kidney Cancers ¹ . <i>Kidney Cancer</i> , 2020, 4, 49-58.	0.4	2
15	Minimally Invasive Surgery for Patients with Locally Advanced and/or Metastatic Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2020, 47, 389-397.	1.8	9
16	Chronic Kidney Disease and Kidney Cancer Surgery: New Perspectives. <i>Journal of Urology</i> , 2020, 203, 475-485.	0.4	25
17	Immunosuppressive milieu of high-risk localized prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 344-344.	1.6	0
18	Small Kidney Tumors. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 588.	7.4	3

#	ARTICLE	IF	CITATIONS
19	AUTHOR REPLY. Urology, 2019, 129, 151-152.	1.0	0
20	Different models for prediction of radical cystectomy postoperative complications and care pathways. Therapeutic Advances in Urology, 2019, 11, 175628721987558.	2.0	11
21	Pin the Tumor on the Kidney: An Evaluation of How Surgeons Translate CT and MRI Data to 3D Models. Urology, 2019, 131, 255-261.	1.0	40
22	Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: clinical trial evidence and experience. Therapeutic Advances in Urology, 2019, 11, 175628721983928.	2.0	13
23	Management of Small Kidney Tumors in 2019. JAMA - Journal of the American Medical Association, 2019, 321, 1622.	7.4	9
24	High Response Rates to Neoadjuvant Chemotherapy in High-Grade Upper Tract Urothelial Carcinoma. Urology, 2019, 129, 146-152.	1.0	29
25	Patient-specific 3D printed and augmented reality kidney and prostate cancer models: impact on patient education. 3D Printing in Medicine, 2019, 5, 4.	3.1	121
26	Personalized Treatment for Small Renal Tumors: Decision Analysis of Competing Causes of Mortality. Radiology, 2019, 290, 732-743.	7.3	12
27	Development of a Novel Prognostic Risk Score for Predicting Complications of Penectomy in the Surgical Management of Penile Cancer. Clinical Genitourinary Cancer, 2019, 17, e123-e129.	1.9	7
28	Use of 3D Printed Models for Complex Renal Surgery: Two Case Presentations: NYU Case of the Month, May 2019. Reviews in Urology, 2019, 21, 118-122.	0.9	0
29	Effect of Malnutrition on Radical Nephroureterectomy Morbidity and Mortality: Opportunity for Preoperative Optimization. Clinical Genitourinary Cancer, 2018, 16, e807-e815.	1.9	7
30	Discordance between Ureteroscopic Biopsy and Final Pathology for Upper Tract Urothelial Carcinoma. Journal of Urology, 2018, 199, 1440-1445.	0.4	53
31	Discriminative Ability of Commonly Used Indexes to Predict Adverse Outcomes After Radical Cystectomy: Comparison of Demographic Data, American Society of Anesthesiologists, Modified Charlson Comorbidity Index, and Modified Frailty Index. Clinical Genitourinary Cancer, 2018, 16, e843-e850.	1.9	31
32	Prediction of Prostate Cancer Risk Among Men Undergoing Combined MRI-targeted and Systematic Biopsy Using Novel Pre-biopsy Nomograms That Incorporate MRI Findings. Urology, 2018, 112, 112-120.	1.0	36
33	Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer. Journal of Clinical Oncology, 2018, 36, 1949-1956.	1.6	110
34	Impact of immunonutrition on radical cystectomy immunoresponse and outcomes; opportunity for peri-operative optimization. Translational Andrology and Urology, 2018, 7, S760-S762.	1.4	2
35	Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy. , 2018, 6, 97.		19
36	The Institutional Learning Curve of Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy: Temporal Improvements in Cancer Detection in 4 Years. Journal of Urology, 2018, 200, 1022-1029.	0.4	64

#	ARTICLE	IF	CITATIONS
37	Three-dimensional Printing and Augmented Reality: Enhanced Precision for Robotic Assisted Partial Nephrectomy. <i>Urology</i> , 2018, 116, 227-228.	1.0	61
38	Percutaneous Ablation Versus Partial and Radical Nephrectomy for T1a Renal Cancer. <i>Annals of Internal Medicine</i> , 2018, 169, 69.	3.9	64
39	Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease. <i>World Journal of Urology</i> , 2017, 35, 327-335.	2.2	26
40	Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2017, 35, 668-680.	1.6	262
41	The Role of Ipsilateral and Contralateral Transrectal Ultrasound-guided Systematic Prostate Biopsy in Men With Unilateral Magnetic Resonance Imaging Lesion Undergoing Magnetic Resonance Imaging-ultrasound Fusion-targeted Prostate Biopsy. <i>Urology</i> , 2017, 102, 178-182.	1.0	54
42	Re: Pak et al.: Utilization Trends and Short-term Outcomes of Robotic Versus Open Radical Cystectomy for Bladder Cancer (<i>Urology</i> 2017;103:117-123) and Borza et al.: No Differences in Population-based Readmissions After Open and Robotic-assisted Cystectomy: Implications for Post-discharge Care (<i>Urology</i> 2017;104:77-83). <i>Urology</i> , 2017, 105, 211.	1.0	0
43	Novel Use of Fluorescence Lymphangiography During Robotic Groin Dissection for Penile Cancer. <i>Urology</i> , 2017, 107, 267.	1.0	17
44	Current Trends in Renal Surgery and Observation for Small Renal Masses. <i>Urologic Clinics of North America</i> , 2017, 44, 169-178.	1.8	16
45	Influence of renal biopsy results on the management of small kidney cancers in older patients: Results from a population-based cohort. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 604.e1-604.e9.	1.6	8
46	Risk Stratification by Urinary Prostate Cancer Gene 3 Testing Before Magnetic Resonance Imaging-Ultrasound Fusion-targeted Prostate Biopsy Among Men With No History of Biopsy. <i>Urology</i> , 2017, 99, 174-179.	1.0	41
47	Robotic Pelvic Exenteration (Cystoprostatectomy and Combined Abdominoperineal Resection) with Double-Barreled Wet Colostomy. <i>Journal of Laparoendoscopic & Advanced Surgical Techniques Part B, Videoscopy</i> , 2017, 27, .	0.2	0
48	Likert score 3 prostate lesions: Association between wholeâ€ lesion ADC metrics and pathologic findings at MRI/ultrasound fusion targeted biopsy. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 43, 325-332.	3.4	25
49	Patterns of surveillance imaging after nephrectomy in the <scp>M</scp>edicare population. <i>BJU International</i> , 2016, 117, 280-286.	2.5	12
50	Predictive value of negative 3T multiparametric magnetic resonance imaging of the prostate on 12â€ core biopsy results. <i>BJU International</i> , 2016, 118, 515-520.	2.5	109
51	A prospective comparative analysis of the accuracy of HistoScanning and multiparametric magnetic resonance imaging in the localization of prostate cancer among men undergoing radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 3.e1-3.e8.	1.6	8
52	Use of MRI in Differentiation of Papillary Renal Cell Carcinoma Subtypes: Qualitative and Quantitative Analysis. <i>American Journal of Roentgenology</i> , 2016, 206, 566-572.	2.2	40
53	Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusionâ€ targeted Prostate Biopsy Outcomes. <i>European Urology</i> , 2016, 69, 512-517.	1.9	163
54	Correlation of DNA damage response (DDR) gene alterations with response to neoadjuvant (neo) dose-dense gemcitabine and cisplatin (ddGC) in urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 5011-5011.	1.6	12

#	ARTICLE	IF	CITATIONS
55	Multicenter prospective phase II trial of neoadjuvant (neo) dose dense gemcitabine and cisplatin (DD-GC) in patients (pts) with muscle-invasive bladder cancer (MIBC).. Journal of Clinical Oncology, 2016, 34, 436-436.	1.6	6
56	Management of Small Kidney Cancers in the New Millennium. JAMA Surgery, 2015, 150, 664.	4.3	75
57	Re: Maxine Sun, Andreas Becker, Zhe Tian, et al. Management of Localized Kidney Cancer: Calculating Cancer-specific Mortality and Competing Risks of Death for Surgery and Nonsurgical Management. Eur Urol 2014;65:235-41. European Urology, 2015, 67, e71.	1.9	0
58	Prebiopsy MRI and MRI-ultrasound Fusion-Targeted Prostate Biopsy in Men With Previous Negative Biopsies: Impact on Repeat Biopsy Strategies. Urology, 2015, 86, 1192-1199.	1.0	71
59	Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy in a Consecutive Cohort of Men with No Previous Biopsy: Reduction of Over Detection through Improved Risk Stratification. Journal of Urology, 2015, 194, 1601-1606.	0.4	87
60	Editorial Comment. Journal of Urology, 2014, 192, 1062-1063.	0.4	0
61	A Prospective, Blinded Comparison of Magnetic Resonance (MR) Imaging-Ultrasound Fusion and Visual Estimation in the Performance of MR-targeted Prostate Biopsy: The PROFUS Trial. European Urology, 2014, 66, 343-351.	1.9	344
62	Novel role of X-linked inhibitor of apoptosis protein (XIAP) in bladder cancer cell invasion and prediction of disease progression.. Journal of Clinical Oncology, 2014, 32, e15504-e15504.	1.6	1
63	Editorial Comment. Urology, 2013, 81, 579-580.	1.0	0
64	Editorial Comment. Urology, 2013, 81, 345-346.	1.0	0
65	Evolving Treatment Paradigms for Renal Cancer. Urologic Clinics of North America, 2012, 39, xiii-xiv.	1.8	2
66	Impact of nephron sparing on kidney function and non-oncologic mortality. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 568-574.	1.6	14
67	Partial Nephrectomy Versus Radical Nephrectomy in Patients With Small Renal Tumors-Is There a Difference in Mortality and Cardiovascular Outcomes?. Journal of Urology, 2009, 181, 55-62.	0.4	703
68	Rational approach to the treatment of a patient with a small renal cortical tumor. Nature Reviews Urology, 2007, 4, 688-691.	1.4	4
69	Surgery Insight: advances in techniques for open partial nephrectomy. Nature Reviews Urology, 2007, 4, 444-450.	1.4	12